Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
16
|
pubmed:dateCreated |
1988-12-2
|
pubmed:abstractText |
Left ventricular (LV) hypertrophy is known to be an independent risk factor for cardiac death, but its significance in non-Q-wave acute myocardial infarction (AMI) has not been assessed previously. In a randomized diltiazem-placebo-controlled therapeutic trial of non-Q-wave AMI confirmed by creatine kinase-MB (CK-MB), 126 of 544 patients (23%) exhibited LV hypertrophy using standard voltage criteria. Compared to patients without LV hypertrophy, patients with LV hypertrophy were significantly older (65 vs 60 years, p less than 0.0001) and had smaller peak adjusted CK levels (490 +/- 376 vs 666 +/- 726 IU/liter, p less than 0.001) than patients without LV hypertrophy. Patients with and without LV hypertrophy did not differ significantly in acute mortality during hospitalization, progression to Q waves, reinfarction by CK-MB criteria or angina associated with transient electrocardiographic changes. Compared with patients without LV hypertrophy, those patients with non-Q-wave AMI and LV hypertrophy had a 2-fold higher incidence of reinfarction (24 vs 12%, p less than 0.005) and death (19 vs 9%, p = 0.044) during the first year of follow-up. Multivariate regression analysis revealed that the relative risk of death and reinfarction during the initial year after AMI was increased by a factor of 1.7 and 2.1 among patients with LV hypertrophy, respectively. It was therefore concluded that, although patients with LV hypertrophy and non-Q-wave AMI have smaller enzymatic infarcts and the same short-term prognosis as do patients without LV hypertrophy, their reinfarction and mortality rates are significantly increased during the first year of follow-up.(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0002-9149
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
62
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1000-4
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:2973215-Age Factors,
pubmed-meshheading:2973215-Cardiomegaly,
pubmed-meshheading:2973215-Clinical Trials as Topic,
pubmed-meshheading:2973215-Creatine Kinase,
pubmed-meshheading:2973215-Diltiazem,
pubmed-meshheading:2973215-Electrocardiography,
pubmed-meshheading:2973215-Humans,
pubmed-meshheading:2973215-Isoenzymes,
pubmed-meshheading:2973215-Myocardial Infarction,
pubmed-meshheading:2973215-Prognosis,
pubmed-meshheading:2973215-Random Allocation,
pubmed-meshheading:2973215-Regression Analysis,
pubmed-meshheading:2973215-Retrospective Studies,
pubmed-meshheading:2973215-Risk Factors
|
pubmed:year |
1988
|
pubmed:articleTitle |
Clinical significance and prognostic importance of left ventricular hypertrophy in non-Q-wave acute myocardial infarction.
|
pubmed:affiliation |
Department of Internal Medicine, Harper Hospital/Detroit Medical Center, Michigan 48201.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial
|